AbbVie Inc.
NASDAQ: ABBVKey stats
Price chart
About AbbVie Inc.
Biotechnology
Company profile
- IPO date
- Jan 2, 2013
- Website
- www.abbvie.com
Healthcare peers
How ABBV compares to other large companies in the same sector.
| Company | Price | Today | Market cap | P/E |
|---|---|---|---|---|
 LLY Eli Lilly and Company | $939.49 | -1.64% | $887.63B | 43.01 |
 JNJ Johnson & Johnson | $238.48 | -1.17% | $574.36B | 21.43 |
 MRK Merck & Co. | $121.44 | -1.01% | $300.20B | 16.45 |
 UNH UnitedHealth Group | $304.35 | -0.83% | $276.23B | 22.91 |
 PFE Pfizer Inc. | $26.93 | -1.07% | $153.07B | 19.70 |
Wall Street analyst ratings
DollarScout analysis
Editorial, not advice. See our methodology.
Bull case
AbbVie has a robust product portfolio that includes well-known drugs like Humira, Skyrizi, and Rinvoq, which have shown strong sales performance. Humira, while facing biosimilar competition, remains a key revenue driver. The company's focus on expanding its immunology and oncology pipeline is a testament to its competitive moat and innovation strength. AbbVie is also investing in new therapies with promising clinical studies, potentially diversifying its revenue streams. The strong dividend yield of 3.1694% also adds a layer of appeal to income-focused investors seeking reliable payouts.
Bear case
AbbVie's P/E ratio of 87.03 is significantly higher than many peers, suggesting the stock could be overvalued if growth doesn't meet expectations. While Humira has historically been a cash cow, its revenue is under threat from generic competition, especially in international markets. The company's reliance on a few flagship drugs exposes it to substantial risk if these drugs face regulatory pushback, patent cliffs, or competition. The pharmaceutical industry is intensely competitive, with fierce players like Pfizer and Johnson & Johnson aiming for market share in similar segments. Additionally, changing healthcare policies and pricing pressures pose risks to profitability.
Who should buy ABBV
AbbVie might suit long-term dividend investors who can tolerate high volatility and prioritize regular income. Suitable for those with a 5+ year horizon looking to benefit from a strong dividend yield and potential capital appreciation from pharmaceutical innovations. It may also appeal to those who believe in the company's strong R&D pipeline and the ability to bring new successful drugs to market.
Key risks
- Heavy reliance on a few key products like Humira for revenue. - Potential overvaluation reflected in high P/E ratio. - Increasing biosimilar competition in the immunology sector. - Regulatory challenges and healthcare policy changes that could impact pricing and profitability.
Where to buy ABBV
Open an account with a broker we've reviewed and start trading AbbVie Inc. today.
Want to practice first? Try the free Stock Trading Simulator with $100,000 virtual cash.
Recent ABBV news
AbbVie (NYSE: ABBV) today announced that late-breaking results from the Phase 2 IMGN853-0420 trial will be presented in an oral session at the 2026 Society of Gynecologic Oncology (SGO) Annual Meeting (San Juan, Puerto Rico; April 10-13, 2026). The study evaluated the potential efficacy and safety of mirvetuximab soravtansine-gynx, a first-in-class antibody-drug conjugate (ADC), in combination with carboplatin followed by maintenance of mirvetuximab soravtansine-gynx monotherapy, in patients wit
Preview next weekâs stock market eventsâearnings (GS, JPM, BAC, NFLX), IPOs, dividends, and key dataâwith Wall Street Week Ahead.
AbbVie has filed a legal challenge seeking to narrow and clarify who counts as an "eligible patient" under the federal 340B drug discount program. The case focuses on how hospitals and clinics can access discounted AbbVie medicines for patients treated in different care settings. This move could influence how 340B discounts are applied across the US healthcare system, with implications for pricing, provider budgets and patient access. For investors watching AbbVie, ticker NYSE:ABBV, this...
If you are wondering whether AbbVie at around US$207.94 is still offering value or starting to look stretched, the next sections will help you frame that question clearly. The stock has seen a 0.4% decline over the last 7 days and is down 8.7% over the past month and 9.3% year to date, while the 1 year return sits at 22.8% and the 3 and 5 year returns are 42.1% and 130.5% respectively. Recent headlines around AbbVie have focused on its position in large cap pharmaceuticals and ongoing...
Phase 1 studies showed that one shot of ORKA-001 lasted long enough to allow dosing twice-a-year—or even once-a-year.
Health care stocks declined late Friday afternoon, with the NYSE Health Care Index falling 1.1% and
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the legendary stocks that return 100 times your money.
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read the full list here.
Disclaimer: The information on this page is provided for informational and educational purposes only and should not be considered financial, investment, or trading advice. DollarScout does not recommend buying or selling any specific security. Stock data may be delayed. Past performance is not indicative of future results. Always do your own research and consult a licensed financial advisor before making investment decisions.